Product and Geographic Sales Information (Tables)

9 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

Schedule of Revenue by reportable segment

The tables below show the Company’s disaggregated revenue for the periods presented:

	Three Months Ended September 30,
	2021		2020
Subscription revenues	$	246,467	$	222,069
Transactional revenues	85,354		64,398
Re-occurring revenues	110,368		—
Total revenues, gross	442,189		286,467
Deferred revenues adjustment (1)	(72)		(2,107)
Total revenues, net	$	442,117	$	284,360
(1) Reflects the deferred revenue adjustment as a result of purchase accounting.
	Nine Months Ended September 30,
	2021		2020
Subscription revenues	$	725,121	$	631,873
Transactional revenues	259,300		174,000
Re-occurring revenues	336,236		—
Total revenues, gross	1,320,657		805,873
Deferred revenues adjustment (1)	(4,465)		(7,421)
Total revenues, net	$	1,316,192	$	798,452
(1) Reflects the deferred revenue adjustment as a result of purchase accounting.

The following table summarizes revenue by reportable segment for the periods indicated:

	Three Months Ended September 30,
	2021		2020
Science Segment	$	200,821	$	188,701
Intellectual Property Segment	241,296		95,659
Total Revenues	$	442,117	$	284,360
	Nine Months Ended September 30,
	2021		2020
Science Segment	$	594,380	$	514,774
Intellectual Property Segment	721,812		283,678
Total Revenues	$	1,316,192	$	798,452

Schedule of Segment Reporting Information, by Segment

Adjusted EBITDA by segment

The following table presents segment profitability and a reconciliation to net income for the periods indicated:

	Three Months Ended September 30,
	2021		2020 (As Restated)
Science Segment Adjusted EBITDA	$	113,771	$	83,310
Intellectual Property Segment Adjusted EBITDA	76,225		24,897
Total Adjusted EBITDA	$	189,996	$	108,207
(Provision) benefit for income taxes	(3,579)		(4,325)
Depreciation and amortization	(130,683)		(68,614)
Interest, net	(65,194)		(20,244)
Deferred revenues adjustment	(72)		(2,107)
Transaction related costs	(11,851)		(34,938)
Share-based compensation expense	(11,997)		(6,796)
Restructuring and impairment	(15,621)		(3,192)
Mark to market adjustment on financial instruments	83,013		(144,753)
Other	(10,700)		(5,224)
Net income (loss)	$	23,312	$	(181,986)
Dividends on preferred shares	(22,431)		—
Net income (loss) attributable to ordinary shares	$	881	$	(181,986)
	Nine Months Ended September 30,
	2021		2020 (As Restated)
Science Segment Adjusted EBITDA	$	305,119	$	226,551
Intellectual Property Segment Adjusted EBITDA	238,696		59,997
Total Adjusted EBITDA	$	543,815	$	286,548
Provision for income taxes	(18,016)		(13,693)
Depreciation and amortization	(392,513)		(176,200)
Interest, net	(141,156)		(72,306)
Deferred revenues adjustment	(4,465)		(7,421)
Transaction related costs	1,599		(70,154)
Share-based compensation expense	(38,518)		(31,121)
Restructuring and impairment	(121,988)		(26,792)
Mark to market adjustment on financial instruments	113,207		(224,175)
Other	(24,817)		(1,586)
Net loss	$	(82,852)	$	(336,900)
Dividends on preferred shares	(22,431)		—
Net loss attributable to ordinary shares	$	(105,283)	$	(336,900)